Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

BACKGROUND: Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus que...

Descripción completa

Detalles Bibliográficos
Autores principales: Justice, Jamie N., Nambiar, Anoop M., Tchkonia, Tamar, LeBrasseur, Nathan K., Pascual, Rodolfo, Hashmi, Shahrukh K., Prata, Larissa, Masternak, Michal M., Kritchevsky, Stephen B., Musi, Nicolas, Kirkland, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412088/
https://www.ncbi.nlm.nih.gov/pubmed/30616998
http://dx.doi.org/10.1016/j.ebiom.2018.12.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412088/
https://www.ncbi.nlm.nih.gov/pubmed/30616998
http://dx.doi.org/10.1016/j.ebiom.2018.12.052

Ejemplares similares